In addition to chemotherapy, targeted medications have been created to treat cancer. These medications only impact cancer cells, sparing normal cells. A novel targeted therapy for the treatment of acute myeloid leukaemia is called venetoclax (AML). In Finland, Venetoclax just received market
Brisbane [Australia], June 16 (ANI): New QIMR Berghofer research has identified how an early genetic change in blood and bone marrow cells paves the way for the development of some blood cancers.